Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SDCBP | O00560 | 3/20 | 0.35 |
| ▸ | SDC2 | P34741 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23706157 | 0.84 | KMT2A (0.45) | TDP1L3MBTL1MEN1KMT2ASDCBP | |
| SCHEMBL28359571 | 0.82 | MEN1 (0.36) | HSD17B3TDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL23309876 | 0.82 | MEN1 (0.36) | HSD17B3TDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL23706266 | 0.80 | NPC1 (0.42) | TDP1L3MBTL1MEN1KMT2ASDCBP | |
| SCHEMBL18793920 | 0.78 | MEN1 (0.41) | TDP1L3MBTL1MEN1KMT2AGABRA1 | |
| SCHEMBL2178347 | 0.75 | GABRA1 (0.36) | HSD17B3TDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL18765683 | 0.74 | GABRA1 (0.43) | HSD17B3TDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL16099526 | 0.73 | SDCBP (0.47) | HSD17B3MEN1KMT2ASDCBPSDC2 | |
| SCHEMBL28616767 | 0.72 | SDCBP (0.40) | HSD17B3MEN1KMT2ASDCBPSDC2 | |
| SCHEMBL23706107 | 0.71 | THRB (0.44) | TDP1L3MBTL1MEN1KMT2ASDCBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3892272-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3892272-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3445357-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200102298-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2017185036-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | HSD17B3 3509/4885TDP1 3724/4885L3MBTL1 1012/4885 |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | HSD17B3 3509/4885TDP1 3724/4885L3MBTL1 1012/4885 |
| US-20200102298-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | HSD17B3 3509/4885TDP1 3724/4885L3MBTL1 1012/4885 |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | HSD17B3 3509/4885TDP1 3724/4885L3MBTL1 1012/4885 |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | HSD17B3 3509/4885TDP1 3724/4885L3MBTL1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.